35 active not recruiting, 29 recruiting, 19 terminated, 18 completed. 124 Phase 2, 20 Phase 1, 4 Phase 3.
Follow Imfinzi: new trials by email Literature Review of Imfinzi trials Research Report on Imfinzi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-12-10 | 2026-06-10 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Not yet recruiting | Mehmet Akce | 29 | 2026-11-01 | 2026-11-04 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-10-12 | 2026-11-06 |
| Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) Biological: Fecal Microbiota Transplantation, Durvalumab, Paclitaxel - Non Small Cell Lung Cancer, Respiratory Tract Neoplasm | Phase 2 | Not yet recruiting | Fundación GECP | 68 | 2026-09-15 | 2026-05-05 |
| TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma Durvalumab - Esophagogastric Adenocarcinoma | Phase 2 | Not yet recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 101 | 2026-07-01 | 2026-04-02 |
| Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Sacituzumab govitecan, Atezolizumab, Durvalumab - Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Bindu R Potugari | 35 | 2026-05-14 | 2026-07-28 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement Pemigatinib, Durvalumab - Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement | Phase 2 | Recruiting | Mehmet Akce | 38 | 2026-01-27 | 2026-10-05 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 45 | 2025-04-08 | 2026-11-16 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Biospecimen Collection, Computed Tomography, Durvalumab - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 2 | Recruiting | Yuanquan Yang | 24 | 2024-12-30 | 2026-10-01 |
| Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) Zanzalintinib, Durvalumab, Tremelimumab - Hepatocellular Carcinoma | Phase 2 | Recruiting | Anwaar Saeed | 40 | 2024-12-18 | 2026-11-13 |
| Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis Tremelimumab, Durvalumab - Hepatocellular Carcinoma, Cirrhosis, Liver | Phase 2 | Recruiting | The University of Texas Health Science Center at San Antonio | 32 | 2024-12-02 | 2026-01-06 |
| Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) Durvalumab, Olaparib - Small Cell Lung Carcinoma | Phase 2 | Enrolling by invitation | University of Cologne | 29 | 2024-10-09 | 2025-05-20 |
| Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) Durvalumab, Olaparib - Cholangiocarcinoma | Phase 2 | Recruiting | Australasian Gastro-Intestinal Trials Group | 40 | 2024-09-23 | 2026-05-06 |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC RP2, Bevacizumab, Atezolizumab - Hepatocellular Carcinoma, Biliary Tract Cancer | Phase 2 | Recruiting | Replimune, Inc. | 60 | 2024-08-01 | 2026-04-02 |
Showing 20 of 124. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (24) · Lung Neoplasms (19) · Carcinoma, Hepatocellular (10) · Cholangiocarcinoma (10) · Small Cell Lung Carcinoma (10) · Urinary Bladder Neoplasms (7) · Pancreatic Neoplasms (6) · Biliary Tract Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Breast Neoplasms (4) · Colorectal Neoplasms (4) · Bile Duct Neoplasms (3) · Carcinoma, Renal Cell (3) · Carcinoma, Transitional Cell (3) · Fallopian Tube Neoplasms (3)
National Cancer Institute (NCI) (13) · M.D. Anderson Cancer Center (12) · University Health Network, Toronto (5) · Mayo Clinic (4) · University of Washington (4) · Australasian Gastro-Intestinal Trials Group (3) · Jonsson Comprehensive Cancer Center (3) · SWOG Cancer Research Network (3) · Washington University School of Medicine (3) · AstraZeneca (2) · Canadian Cancer Trials Group (2) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) · Mehmet Akce (2) · Stanford University (2) · AGO Research GmbH (1)
United States (84) · Canada (13) · Germany (6) · Italy (6) · Spain (6) · Australia (5) · Netherlands (4) · South Korea (4) · Belgium (2) · China (2) · Norway (2) · Poland (2) · Denmark (1) · Estonia (1) · Finland (1)
Amir A Jazaeri (2) · Jing Zeng (2) · Lillian Siu, MD (2) · Mehmet Akce, MD (2) · Salah-Eddin Al-Batran, Prof. Dr. (2) · Vassiliki Papadimitrakopoulou (2) · A P Chen (1) · Adel Kardosh (1) · Afshin Dowlati (1) · Alain P Algazi, MD (1) · Albert Chang (1) · Albert J Chang (1) · Alberto Sobrero, MD (1) · Albiruni Razak, MD (1)
PMID 10673991, PMID 16773629, PMID 17997439, PMID 19097774, PMID 21555688, PMID 23770567, PMID 24209604, PMID 24472710, PMID 24476821, PMID 25428503, PMID 26487582, PMID 26541610, PMID 27140411, PMID 27262113, PMID 27269937, PMID 27324051, PMID 27345655, PMID 27726966, PMID 28078238, PMID 28259287, PMID 28271869, PMID 28337197, PMID 28481359, PMID 28817753, PMID 28885881, PMID 32027845, PMID 32379280, PMID 32379297, PMID 33714009, PMID 34006499, PMID 34389237, PMID 34429332, PMID 34663638, PMID 35033226, PMID 36007218, PMID 36889516, PMID 36912078, PMID 37476372, PMID 38009662, PMID 38127487, PMID 38205877, PMID 38410608, PMID 39178370, PMID 39521433, PMID 39551064, PMID 39631846, PMID 39886125, PMID 39965889, PMID 40466026, PMID 40580957
2018 (3), U10CA180820 (3), U10CA180868 (3), U10CA180888 (3), 2023 (2), 2025 (2), 2014 (1), 2015 (1), P30CA015083 (1), P30CA015704 (1), P30CA016056 (1), P30CA016672 (1), P30CA033572 (1), P30CA043703 (1), P30CA060553 (1)